$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Sotoracib (AMG 510) belongs to the first generation of targeted drugs and its clinical application status
2026-02-01 22:25:32
Check Details
Analysis of the differences between the efficacy, price and original drug of Laos Lucius version of adagrasib (Krazati)
2026-02-01 22:25:32
Check Details
Detailed interpretation of the instructions and precautions for larotrectinib (Vitaika)
2026-02-01 22:25:32
Check Details
A comprehensive analysis of the miraculous effects and indications of Seleniso (Silvio)
2026-02-01 22:25:32
Check Details
Full analysis of Vigabatrin price and formal purchasing channels
2026-02-01 22:25:32
Check Details
The correct way to take Moboxetinib (Anvili) and daily dosage recommendations
2026-02-01 22:25:32
Check Details
Tepotinib latest price and market trend analysis in 2025
2026-02-01 22:25:32
Check Details
Analysis of the efficacy, common side effects and treatment methods of Regorafenib (Belvango)
2026-02-01 22:25:32
Check Details
Analysis of the scope of indications and clinical application effects of Pazopanib (Victor)
2026-02-01 22:25:32
Check Details
Detailed instructions for Opicapone and analysis of medication precautions
2026-02-01 22:25:32
Check Details
Effects of long-term use of Fenelidone (Keshenda) for one year on renal failure
2026-02-01 22:25:32
Check Details
The correct way to take rasagiline (Anzilai) and daily precautions
2026-02-01 22:25:32
Check Details
1
2
...
1911
1912
1913
1914
1915
1916
1917
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
2
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
9
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
10
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
11
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
12
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide